melphalan - CISMeF

Preferred Label : melphalan;

MeSH definition : An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.;

MeSH synonym : mustard, phenylalanine; l-pam; phenylalanine mustard; 4-(bis(2-chloroethyl)amino)phenylalanine;

MeSH hyponym : alkeran;

Related MeSH term : sarcolysine; medphalan; sarkolysin; Merphalan;

MeSH CAS label : L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-;

MeSH Related Number : 148-82-3 (Melphalan);

Registry Number MeSH : 148-82-3;

Wikipedia link : https://en.wikipedia.org/wiki/Melphalan;

Codes EINECS : 205-726-3;

Is substance : O;

UNII : Q41OR9510P;

InChIKey : SGDBTWWWUNNDEQ-LBPRGKRZSA-N;

Details

Origin ID

D008558;

UMLS CUI

C0025241;

ATC code(s)
- melphalan [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Integrin Alpha4/Beta7 [NCIt concept]
- Phenylalanine mustard [ICHI extension code]
- Primary acquired melanocytic nevus of conjunctiva (disorder) [SNOMED CT concept]
- Sarcolysin [ICD-11 Extension code]
- Sarcolysin [ICHI extension code]
- Sarcolysin [NCIt concept]
CISMeF manual mappings
- Melphalan poisoning (disorder) [SNOMED CT concept]
- melphalan [Substance BNPC]
Currated CISMeF NLP mapping
- Melphalan [ICD-11 Extension code]
- Melphalan [ICHI extension code]
- Melphalan [SMS substance]
- Melphalan [NCIt concept]
- Melphalan (substance) [SNOMED CT concept]
- melphalan [SNOMED Notion]
Pharmacological action(s)
- antineoplastic agents, alkylating [MeSH Descriptor]
- myeloablative agonists [MeSH Descriptor]
Record concept(s)
- alkeran [MeSH concept]
- medphalan [MeSH concept]
- melphalan [MeSH concept]
- sarkolysin [MeSH concept]
Related MeSH Supplementary Concept(s)
- (COMPADRI)-III protocol [MeSH Supplementary Concept]
- 1,3-dipalmitoyl-2-(4'-(bis(2''-chloroethyl)amino)phenylalaninoyl)glycerol [MeSH Supplementary Concept]
- 1-(4-butanoyl-(4-bis(2-chloroethyl)amino)phenylalanine ethyl ester)-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one [MeSH Supplementary Concept]
- 2-methyl-5-bis(beta-chloroethyl)aminophenylalanine [MeSH Supplementary Concept]
- 4-bis(2-hydroxyethyl)amino-L-phenylalanine [MeSH Supplementary Concept]
- ABCM protocol [MeSH Supplementary Concept]
- AP protocol 2 [MeSH Supplementary Concept]
- BEAM protocol [MeSH Supplementary Concept]
- BEAM regimen [MeSH Supplementary Concept]
- BEM protocol [MeSH Supplementary Concept]
- BMP protocol [MeSH Supplementary Concept]
- C-Mel [MeSH Supplementary Concept]
- CAD protocol 1 [MeSH Supplementary Concept]
- CAV regimen [MeSH Supplementary Concept]
- CAVP protocol [MeSH Supplementary Concept]
- CMCp protocol [MeSH Supplementary Concept]
- CMVP regimen [MeSH Supplementary Concept]
- COMPA protocol [MeSH Supplementary Concept]
- Dexa-BEAM protocol [MeSH Supplementary Concept]
- FBM protocol [MeSH Supplementary Concept]
- FMVMP regimen [MeSH Supplementary Concept]
- K-18 conjugate [MeSH Supplementary Concept]
- M-2 protocol [MeSH Supplementary Concept]
- MAC conditioning regimen [MeSH Supplementary Concept]
- MCNU-VMP protocol [MeSH Supplementary Concept]
- MCPD protocol [MeSH Supplementary Concept]
- MDT protocol [MeSH Supplementary Concept]
- MEC regimen [MeSH Supplementary Concept]
- MFP protocol [MeSH Supplementary Concept]
- MMC protocol [MeSH Supplementary Concept]
- MMM protocol 1 [MeSH Supplementary Concept]
- MMPP protocol [MeSH Supplementary Concept]
- MOCCA protocol [MeSH Supplementary Concept]
- MOPPEBVCAD protocol [MeSH Supplementary Concept]
- MP combination [MeSH Supplementary Concept]
- MPCCV protocol [MeSH Supplementary Concept]
- MPP protocol [MeSH Supplementary Concept]
- MiNa protocol [MeSH Supplementary Concept]
- N-acetylmelphalan [MeSH Supplementary Concept]
- OMEC regimen [MeSH Supplementary Concept]
- PAFT protocol [MeSH Supplementary Concept]
- PAMP protocol [MeSH Supplementary Concept]
- PAVe protocol 1 [MeSH Supplementary Concept]
- PFT protocol [MeSH Supplementary Concept]
- PMF protocol [MeSH Supplementary Concept]
- PMP protocol [MeSH Supplementary Concept]
- ROAD-IN protocol [MeSH Supplementary Concept]
- TMC regimen [MeSH Supplementary Concept]
- VAMP-ME protocol [MeSH Supplementary Concept]
- VBAMDex protocol [MeSH Supplementary Concept]
- VCSP protocol [MeSH Supplementary Concept]
- VMCP protocol [MeSH Supplementary Concept]
- VMP-3 protocol [MeSH Supplementary Concept]
- VinMCP protocol [MeSH Supplementary Concept]
- alpha-MSH-melphalan conjugate [MeSH Supplementary Concept]
- antineoplastic agent K 18 [MeSH Supplementary Concept]
- asalin [MeSH Supplementary Concept]
- beta-alanylmelphalan [MeSH Supplementary Concept]
- enkephalin-Leu, Ala(2)-melphalan methyl ester- [MeSH Supplementary Concept]
- iodomelphalan [MeSH Supplementary Concept]
- isopropyl melphalan [MeSH Supplementary Concept]
- leucine sarcolysine [MeSH Supplementary Concept]
- mecaphane [MeSH Supplementary Concept]
- melflufen [MeSH Supplementary Concept]
- melphalan-N-4-hydroxyphenoxyacetamide [MeSH Supplementary Concept]
- metamelfalan [MeSH Supplementary Concept]
- methyl 3-(4-(bis(2-chloroethyl)amino)phenyl)-2-(2-(4-((N-isopropyl)amidino)phenyl)furan-5-carboxamido)propanoate [MeSH Supplementary Concept]
- monohydroxymelphalan [MeSH Supplementary Concept]
- ocaphane [MeSH Supplementary Concept]
- prophalan [MeSH Supplementary Concept]
- sarcolysine acridine [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Melphalan [ICD-11 Extension code]
- Melphalan [NCIt concept]
- Melphalan (substance) [SNOMED CT concept]
- Product containing melphalan (medicinal product) [SNOMED CT concept]
- melphalan [ATC Code]
- melphalan [Substance BNPC]
- melphalan [SNOMED Notion]
Validated automatic mappings to BTNT
- melphalan [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients